Publications, Pharmaceutical

Using pharmacokinetics to confirm bioequivalence in fluticasone DPIs

Streamlining the complexities of confirming the bioequivalence of generic orally inhaled drug products by would be helpful in reducing the costs of widely used respiratory therapeutics.

This paper describes pharmacokinetic studies of three fluticasone propionate dry powder inhaler formulations with respect to their effectiveness in detecting differences in regional deposition. The formulations were chosen for their ability to deliver deposition in different areas of the lung while at the same time ensuring a comparable overall dose. Systemic pharmacokinetics were assessed in a randomized, double-blind, four-way, crossover study, with 24 healthy volunteers. The results support the use of pharmacokinetic studies to provide relevant data for the assessment of pulmonary performance via parameters such as regional deposition, available dose, and residence time.

Download Publication
6 Feb 2021

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

24 Apr 2024

Advancing OINDP Clinical Trials with Speed and Efficiency: Strategies for Success

Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
24 Apr 2024

Exploring Nasal Casts in Nasal Drug Development

Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
22 Apr 2024

Navigating the Shift to more sustainable Low GWP propellants in pMDIs

Publications, Pharmaceutical, Sustainability, Brand Differentiation, Market Insights, Product Solutions

Read More
26 Mar 2024

Optimizing Preclinical Studies for Intranasal and Pulmonary Programs

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
1 2 3 19
Back To Top